Artificial Intelligence In Drug Repurposing Market Size, Share & Trends Analysis Report By Component (Software & Platform, Services), By Technology (Machine Learning Algorithms, NLP), By Application (Oncology, Rare & Orphan Diseases), By End Use, By Regio

Artificial Intelligence In Drug Repurposing Market Summary

The global artificial intelligence in drug repurposing market size was estimated at USD 1.23 billion in 2025 and is projected to reach USD 5.71 billion by 2033, growing at a CAGR of 21.18% from 2026 to 2033. Rising demand for cost-effective drug development, increasing clinical trials in drug repurposing, and growing prevalence of rare and complex diseases are significant factors contributing to market growth.

In addition, growing focus on precision medicine and targeted drug development and improvements in computing power and cloud infrastructure are some other factors fueling market growth.

The rising demand for cost-effective drug development strategies substantially drives the AI in drug repurposing market. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments.

AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.

Furthermore, the rising prevalence of rare diseases propels market growth further. For instance, according to the data published by The Lancet Journal in March 2024, around 300 million people live with rare diseases, affecting around 3.5% - 5.9% of the global population. Moreover, around 80% of rare diseases are genetically caused, almost 70% of which are present in childhood. AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs, thus expediting treatment access.

Global Artificial Intelligence In Drug Repurposing Market Report Segmentation

This report forecasts, revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented global artificial intelligence in drug repurposing market report based on component, technology, application, end use, and region.

• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Software & Platforms
• Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Machine Learning/Deep Learning
• Natural Language Processing (NLP)
• Knowledge Graphs & Network-Based AI
• Generative AI & Large Language Models (LLMs)
• Computer Vision
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Rare & Orphan Diseases
• Other Therapeutic Areas
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• MEA
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more